NPCE on XNAS, Health Care, Neuropace, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 39% in one month as quarterly revenue dropped 16% to $23.1M.
GoodThree insiders bought $302K of shares in the last 90 days
GoodFederal contracts and grants rose to $2.1M from $368K a year earlier
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 2 Mar 2027 (an estimate: a year ago it reported on 3 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $23.1M, net loss $3.3M.
31 Dec 2021RevenueNet incomeNet losstallest bar $27.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$23.1M
-$3.3M
30 Jun 2026
$22.8M
-$6.2M
31 Mar 2026
$22.1M
-$6.7M
31 Dec 2025
$26.6M
-$2.7M
30 Sep 2025
$27.4M
-$3.5M
30 Jun 2025
$23.5M
-$8.7M
31 Mar 2025
$22.5M
-$6.6M
31 Dec 2024
$21.5M
-$5.2M
30 Sep 2024
$21.1M
-$5.5M
30 Jun 2024
$19.3M
-$7.5M
31 Mar 2024
$18.1M
-$8.9M
31 Dec 2023
$18.0M
-$6.2M
30 Sep 2023
$16.4M
-$7.3M
30 Jun 2023
$16.5M
-$9.1M
31 Mar 2023
$14.5M
-$10.4M
31 Dec 2022
$12.8M
-$11.1M
30 Sep 2022
$11.2M
-$11.8M
30 Jun 2022
$10.2M
-$12.7M
31 Mar 2022
$11.4M
-$11.5M
31 Dec 2021
$11.0M
-$10.7M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$94.6M
$86.8M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+8.9%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$18.9M
-$24.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.56
-$0.75
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
81.4%
79.4%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-15.4%
-24.2%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-20.0%
-27.6%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-126%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$12.4M
-$16.6M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$49.2M
$60.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$59.2M
$58.7M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$9.9M
-$1.3M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
5.1
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.33
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.9
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
3.0
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
23.8
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$302K
bought $302K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-9.7%
102 13F filers vs 113
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
77%
26.5M shares held by 13F filers (30 Sep 2026) of 34.5M outstanding (10 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.5%
858K shares sold short (30 Oct 2026) of 34.5M outstanding (10 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.5
858K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-3.1%
886K shares sold short in the report before, 858K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
51%
51% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
21
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-16%
$23.1M vs $27.4M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$2.1M
the 12 months before: $368K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$140K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
28
28 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.0×
28 articles in the last 7 days; its usual week has 3.5.
Unusual now sharp changes in the last 90 days, compared with its own past
Insider buying $302K, 3 insiders
Price $7.95 on 20 Nov 2026, -41% over 12 months (12-month range $7.56 to $19.29)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $97K in the last 12 months (the 12 months before: -$53.3M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.Revenue per quarter. Revenue $23.1M in the latest quarter, -16% on a year earlier.Capital spending per quarter. Capital spending $16K in the latest quarter, -47% on a year earlier.Institutional holders (13F filers). 102 13F filers reported holding it in the latest 13F quarter, +31% on a year earlier.Federal obligations. Federal obligations: $285K published in the last 12 months, -86% on the 12 months before.Lobbying spend. Lobbying spend: $140K published in the last 12 months, +75% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
21 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 90%, Finance & accounting 5%, Test, quality & reliability 5%.
Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 May 2025
New
LMH Strategic Solutionsfor Neuropace, Inc.
Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.Medicare/Medicaid
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 1.1M shares sold short in the 15 Oct 2025 report, 2.1× the same report last year.
Same report last year: 509K; its normal report is 375K.
See the evidence
This period
1.1M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
125K
How far from its usual level
+3.8
Same report last year
509K
History used
1,629 days
the 15 Oct 2025 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 30 Sep 2025 report, 2.1× the same report last year.
Same report last year: 533K; its normal report is 375K.
See the evidence
This period
1.1M (the 30 Sep 2025 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
125K
How far from its usual level
+4.0
Same report last year
533K
History used
1,614 days
the 30 Sep 2025 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 997K shares sold short in the 15 Aug 2025 report, 2.0× the same report last year.
Same report last year: 488K; its normal report is 375K.
See the evidence
This period
997K (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
118K
How far from its usual level
+3.5
Same report last year
488K
History used
1,568 days
the 15 Aug 2025 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year.
Same report last year: 478K; its normal report is 375K.
See the evidence
This period
1.1M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
112K
How far from its usual level
+4.4
Same report last year
478K
History used
1,553 days
the 31 Jul 2025 report24 earlier reportsnormal: 375K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 509K shares sold short in the 15 Oct 2024 report, 1.6× the same report last year.
Same report last year: 313K; its normal report is 111K.
See the evidence
This period
509K (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
111K
Typical spread (median absolute deviation)
48K
How far from its usual level
+5.5
Same report last year
313K
History used
1,264 days
the 15 Oct 2024 report24 earlier reportsnormal: 111K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 533K shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.
Same report last year: 307K; its normal report is 111K.
See the evidence
This period
533K (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
111K
Typical spread (median absolute deviation)
48K
How far from its usual level
+5.9
Same report last year
307K
History used
1,249 days
the 30 Sep 2024 report24 earlier reportsnormal: 111K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 506K shares sold short in the 13 Sep 2024 report, 1.4× the same report last year.
Same report last year: 352K; its normal report is 111K.
See the evidence
This period
506K (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
111K
Typical spread (median absolute deviation)
48K
How far from its usual level
+5.5
Same report last year
352K
History used
1,232 days
the 13 Sep 2024 report24 earlier reportsnormal: 111K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 518K shares sold short in the 30 Aug 2024 report, 1.2× the same report last year.
Same report last year: 441K; its normal report is 111K.
See the evidence
This period
518K (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
111K
Typical spread (median absolute deviation)
48K
How far from its usual level
+5.7
Same report last year
441K
History used
1,218 days
the 30 Aug 2024 report24 earlier reportsnormal: 111K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $16.4M for the quarter ended 30 Sep 2023, 1.5× the same quarter last year.
Same quarter last year: $11.2M; its normal quarter is $11.3M.
See the evidence
This period
$16.4M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$11.3M
Typical spread (median absolute deviation)
$996K
How far from its usual level
+3.5
Same quarter last year
$11.2M
History used
1,278 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $11.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $16.5M for the quarter ended 30 Jun 2023, 1.6× the same quarter last year.
Same quarter last year: $10.2M; its normal quarter is $11.3M.
See the evidence
This period
$16.5M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$11.3M
Typical spread (median absolute deviation)
$996K
How far from its usual level
+3.6
Same quarter last year
$10.2M
History used
1,186 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $11.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 43 entries; narrow the window or the kind of data to see older ones.
Not listed: 89 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001528287
Ticker
NPCE
Domain
neuropace.com
Employer name
NeuroPace, Inc. (1 unverified)
Hq location
CA|MOUNTAIN VIEW|94043 (1 unverified)
Lobbying client
neuropace
Name
Neuropace, Inc.
Uei
VV9XSUEG8QD3
Wikidata
Q63969967
DOL H-1B labor condition applications and PERM certifications15 data points9 Mar 2020 to 11 Apr 2022
Federal lobbying disclosures (LDA)1 record, 18 data points1 May 2025 to 30 Sep 2026
SEC Form 13F institutional holdings198 data points30 Jun 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)75 records9 Jan 2017 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)543 data points31 Dec 2019 to 10 Nov 2026
SEC Form 4 insider transactions37 records, 124 data points23 Apr 2021 to 18 Nov 2026
FINRA short interest (twice monthly)395 data points30 Apr 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2802 data points22 Apr 2021 to 20 Nov 2026
USASpending.gov federal awards231 data points27 Mar 2014 to 5 Oct 2026